FilingSEC EDGAR8-K
Adicet Bio Updates Prula-cel Clinical Data in Lupus
· SEC accepted
StageClinical
Filing content
Adicet Bio reported that 50% of evaluable lupus nephritis patients achieved complete renal response and 54% achieved DORIS remission with Prula-cel. The safety profile supports outpatient administration.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…